Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in Pre-treated EGFR-mutated Metastatic NSCLC
NCT02625168Phase 2Completed
- Sponsor
- The University of Hong Kong
- Start
- Jan 2013
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by The University of Hong Kong. Started Jan 2013; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02625168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02625168.